Taxanes in Lung Cancer Therapy
Crc Press Inc (Verlag)
978-0-8247-9892-5 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Exploring topics from pharmacokinetics and tubulin targets to schedule dependence and clinical toxicity profiles, this timely work compiles-in a single source-current information on taxanes and their superior activity against small-cell and non-small-cell lung cancer that will enable researchers to optimize present and future palliative and curative strategies.
Representing international efforts to define the full potential of these chemotherapeutic drugs, Taxanes in Lung Cancer Therapy furnishes results from ongoing studies involving
novel mechanisms of action for paclitaxel and docetaxel
paclitaxel exposure duration as well as drug combinations and sequences
phase II trials with paclitaxel in chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC) patients
the combination of paclitaxel and other active agents, such as cisplatin and ifosfamide, in previously untreated small-cell lung cancer (SCLC) as well as advanced NSCLC
comparisons of survival duration, response rates, and toxicity between taxol and other regimens
the activity of docetaxel against platinum-resistant/refractory NSCLC
and much more!
Written by researchers and clinicians at the forefront of the field, Taxanes in Lung Cancer Therapy is an essential resource for oncologists, pulmonologists, cancer researchers, pharmacologists, research and development personnel in the pharmaceutical industry, and graduate and medical school students in these disciplines.
Taxanes: New Insights into Mechanisms of Drug Action, John J. Wright, Ellen G. Feigal, and Susan G. Arbuck
In Vitro Testing of Paclitaxel and Docetaxel Against Human Lung Cancer Cell Lines: Implications for Clinical Trials, Mark S. Georgiadis and Bruce E. Johnson
Phase II Trials with Paclitaxel in Non-Small-Cell Lung Cancer: North American Experience, Alex Y. Chang
Phase II Results of Taxanes in Lung Cancer: European Experience, Thomas Cerny and A. Calderoni
Paclitaxel in the Treatment of Small-Cell Lung Cancer: North American Experience, David S. Ettinger
Taxanes in Small-Cell Lung Cancer: European Experience, Nick Thatcher, M. Ranson, G. Jayson, and H. Anderson
Phase III Experience with Paclitaxel in Non-Small-Cell Lung Cancer: North American Experience, Philip Bonomi, KyungMann Kim, and David H. Johnson
Phase III Experience wtih Paclitaxel in Non-Small-Cell Lung Cancer: European Experience, Klaus Havemann and Martin Wolf
Docetaxel Trials in Non-Small-Cell Carcinoma of the Lung, Richard J. Gralla
Single-Agent Paclitaxel as Second-Line Chemotherapy for Resistant, Metastatic Non-Small-Cell Lung Cancer, Linda L. Garland, John C. Ruckdeschel, Henry Wagner, Jr., Charles C. Williams, Jr., Gail Shaw, Scott J. Antonia, Mary Heise, Jane Hilstro, and Alan Cantor
Docetaxel in Chemotherapy-Refractory or Recurrent Non-Small-Cell Lung Cancer, Frank V. Fossella, Jin Soo Lee, and Waun Ki Hong
Paclitaxel: Combinations with Cisplatin or Carboplatin in Non-Small-Cell Lung Cancer, Chandra P. Belani
Paclitaxel/Cisplatin Combination in Operable Non-Small-Cell Lung Cancer: European Experience, O. Rixe, L. Belli, J. P. Sculier, Jean Klastersky, and T. LeChevalier
Taxanes in Lung Cancer: Combinations of Paclitaxel and Ifosfamide in Non-Small-Cell Lung Cancer, Ann M. Mauer, Philip C. Hoffman, Gregory A. Masters, Harvey M. Golomb, and Everett E. Vokes
Taxanes and Radiation Therapy in Solid Tumors, Hak Choy, W. Akerley, and H. Safran
| Verlagsort | Bosa Roca |
|---|---|
| Sprache | englisch |
| Maße | 216 x 279 mm |
| Gewicht | 408 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Pneumologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| ISBN-10 | 0-8247-9892-9 / 0824798929 |
| ISBN-13 | 978-0-8247-9892-5 / 9780824798925 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
